Abstract:

This study assesses the trade-off between drug safety and price savings in online drug purchases. Focusing on five brand-name prescription drugs, we acquire 370 drug samples from 41 online pharmacies and test their authenticity. Of the 41 websites, 8 are clearly US-based and verified by the National Association of...

There a few notes should be made in the margins of the article by Italian historian Guido Formigoni, published in "TamTam democratic" and entitled "De Gasperi, Dossetti and the false dilemma statism-subsidiarity."  It seems worth noting that the interesting debate animated by Formigoni is found in the notions of "social...

AEI's Alex Brill finds that Medicaid programs often reimbursed pharmacies for expensive brand-name drugs when alternative generic products were available at a lower cost--costing states in 2009 an estimated $329 million in excessive payments.

In 2009, unnecessary Medicaid spending in Georgia was $25 million--the third highest among all states. Nationwide, Medicaid reimbursement for expensive brand-name drugs over alternative generic products cost an estimated $329 million in excessive payments.

In 2009, unnecessary Medicaid spending in Ohio was $21 million--the fourth highest among all states. Nationwide, Medicaid reimbursement for expensive brand-name drugs over alternative generic products cost an estimated $329 million in excessive payments.

In 2009, unnecessary Medicaid spending in California was $102 million--the highest among all states. Nationwide, Medicaid reimbursement for expensive brand-name drugs over alternative generic products cost an estimated $329 million in excessive payments.

In 2009, unnecessary Medicaid spending in Texas was $31 million--the second highest among all states. Nationally, Medicaid reimbursed pharmacies for expensive brand-name drugs when alternative generic products were available at a lower cost--costing $329 million in excessive payments.

Knowing where all our ingredients come from is the first step toward improving drug quality.